Synapse - Solid Tumor Oncology Division

Results (191)

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: Development of a prognostic model through a crowdsourced challenge with open clinical trial data

Journal Article

Guinney, J.; Wang, T.; Laajala, T. D.; Kanigel Winner, K.; Bare, J. C.; Neto, E. C.; Khan, S. A.; Peddinti, G.; Airola, A.; Pahikkala, T.; more...
Lancet Oncology (2017)

Fulltext@MSK | Save

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: A first-in-human, first-in-class, open-label, phase 1 study

Journal Article

Rudin, C. M.; Pietanza, M. C.; Bauer, T. M.; Ready, N.; Morgensztern, D.; Glisson, B. S.; Byers, L. A.; Johnson, M. L.; Burris, H. A. 3rd; Robert, F.; more...
Lancet Oncology (2017)

Fulltext@MSK | Save

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

Journal Article

Hodi, F. S.; Chesney, J.; Pavlick, A. C.; Robert, C.; Grossmann, K. F.; McDermott, D. F.; Linette, G. P.; Meyer, N.; Giguere, J. K.; Agarwala, S. S.; more...
Lancet Oncology (2016)

Fulltext@MSK | Save

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: An analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database

Journal Article

Franko, J.; Shi, Q.; Meyers, J. P.; Maughan, T. S.; Adams, R. A.; Seymour, M. T.; Saltz, L.; Punt, C. J. A.; Koopman, M.; Tournigand, C.; more...
Lancet Oncology (2016)

Fulltext@MSK | Save

Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

Journal Article

Drilon, A.; Rekhtman, N.; Arcila, M.; Wang, L.; Ni, A.; Albano, M.; Van Voorthuysen, M.; Somwar, R.; Smith, R. S.; Montecalvo, J.; more...
Lancet Oncology (2016)

Fulltext@MSK | Save

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): A multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Journal Article

Sharma, P.; Callahan, M. K.; Bono, P.; Kim, J.; Spiliopoulou, P.; Calvo, E.; Pillai, R. N.; Ott, P. A.; de Braud, F.; Morse, M.; more...
Lancet Oncology (2016)

Fulltext@MSK | Save

Bevacizumab in colorectal cancer: It should have worked

Journal Article

Saltz, L. B.
Lancet Oncology (2016)

Fulltext@MSK | Save

Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: A non-randomised, multicentre, open-label, phase 2 trial

Journal Article

Brose, M. S.; Cabanillas, M. E.; Cohen, E. E. W.; Wirth, L. J.; Riehl, T.; Yue, H.; Sherman, S. I.; Sherman, E. J.
Lancet Oncology (2016)

Fulltext@MSK | Save

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: A multicentre, single-group, open-label, phase 2 trial

Journal Article

Kaufman, H. L.; Russell, J.; Hamid, O.; Bhatia, S.; Terheyden, P.; D'Angelo, S. P.; Shih, K. C.; Lebbé, C.; Linette, G. P.; Milella, M.; more...
Lancet Oncology (2016)

Fulltext@MSK | Save

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: A randomised, open-label, phase 3 trial

Journal Article

Cella, D.; Grünwald, V.; Nathan, P.; Doan, J.; Dastani, H.; Taylor, F.; Bennett, B.; DeRosa, M.; Berry, S.; Broglio, K.; more...
Lancet Oncology (2016)

Fulltext@MSK | Save